8-K: ImmunityBio Reports Third-Quarter 2024 Financial Results, ANKTIVA Sales Exceed Expectations

ImmunityBio announced its third-quarter 2024 financial results, highlighted by ANKTIVA sales surpassing analyst estimates and progress in global regulatory submissions.

Summary

• ImmunityBio reported a net product revenue of approximately $6.0 million for the three months ended September 30, 2024, which exceeded the $1.0 million reported in the prior quarter and surpassed analyst estimates.
• The company's net loss attributable to common stockholders was $85.7 million for the quarter, compared to a net loss of $95.6 million in the same period last year.
• Research and development expenses increased to $50.4 million, while selling, general, and administrative expenses rose to $35.9 million.
• As of September 30, 2024, ImmunityBio had $130.4 million in cash and marketable securities.
• ANKTIVA received a permanent J-code effective January 1, 2025, and has secured coverage for over 200 million medical lives.
• The shelf life of ANKTIVA has been extended from two to three years, with over 125,000 doses available.
• A Marketing Authorization Application (MAA) for ANKTIVA was submitted in the UK on November 1, 2024, and an EU submission is expected in Q4 2024.

Sentiment

Score: 7

Explanation: The document shows positive progress in product sales and regulatory submissions, but the significant net loss and cash burn temper the overall sentiment. The company is making progress but still has financial challenges to overcome.

Positives

• ANKTIVA's sales significantly increased, exceeding both the previous quarter's revenue and analyst estimates.
• The company has secured broad insurance coverage for ANKTIVA, reaching over 200 million medical lives.
• The extension of ANKTIVA's shelf life to three years ensures ample product supply.
• The submission of the MAA in the UK and planned submission in the EU demonstrate progress in global expansion.
• The net loss decreased year-over-year, indicating improved financial performance.

Negatives

• The company reported a net loss of $85.7 million for the quarter.
• Research and development expenses increased by $2.0 million compared to the same period last year.
• Selling, general, and administrative expenses increased by $4.1 million compared to the same period last year.
• The company's cash and marketable securities decreased from $267.4 million at the end of 2023 to $130.4 million as of September 30, 2024.

Risks

• The company is still operating at a significant net loss, which may require additional financing.
• Increased operating expenses could impact future profitability.
• The company faces risks associated with regulatory approvals and commercial launch execution.
• There are risks related to the company's ability to scale manufacturing and commercial supply operations.
• The company's ability to obtain, maintain, protect, and enforce patent protection is a risk.

Future Outlook

The company anticipates submitting a Marketing Authorization Application (MAA) for ANKTIVA in the European Union in Q4 2024 and continues to expand clinical trials globally. They are also focusing on the regulatory development of ANKTIVA in BCG nave bladder cancer and non-small cell lung cancer (NSCLC) patients who have failed checkpoint inhibitors.

Management Comments

• Richard Adcock, President and CEO of ImmunityBio, stated that the U.S. launch of ANKTIVA for NMIBC CIS continues to gain momentum and that the response from urologists and clinical practices has been gratifying.
• Dr. Patrick Soon-Shiong, Executive Chairman, Global Chief Scientific & Medical Officer of ImmunityBio, mentioned that initial clinical trials of ANKTIVA are being designed for high-risk prostate cancer.

Industry Context

The announcement reflects the growing interest in immunotherapies for cancer treatment, particularly in the bladder cancer space. The successful launch and expansion of ANKTIVA aligns with the trend of personalized medicine and the development of novel therapies that activate the immune system. The global expansion plans also indicate a broader industry trend of seeking regulatory approvals in multiple markets.

Comparison to Industry Standards

• The $6.0 million in net product revenue for ANKTIVA is a positive sign, especially compared to the previous quarter's $1.0 million, indicating a successful initial launch. However, it is still relatively small compared to established pharmaceutical companies with blockbuster drugs.
• The company's net loss of $85.7 million is significant, and it will need to demonstrate a clear path to profitability. Companies like Gilead Sciences and Bristol Myers Squibb, which have established immunotherapy products, have much higher revenues and are profitable.
• The expansion of ANKTIVA's shelf life to three years is a positive development, as it reduces the risk of product expiry and waste. This is a common practice in the pharmaceutical industry to ensure product availability.
• The submission of the MAA in the UK and planned submission in the EU are standard steps for companies seeking global market access. Companies like AstraZeneca and Roche have established global regulatory pathways and are benchmarks for this process.
• The clinical trials in BCG nave NMIBC and high-risk prostate cancer are in line with industry trends of exploring new indications for existing therapies. Companies like Merck and Pfizer are also actively involved in clinical trials for various cancer indications.

Stakeholder Impact

• Shareholders may be encouraged by the increased product revenue and progress in regulatory submissions, but concerned about the ongoing net losses.
• Employees may be positively impacted by the company's growth and expansion.
• Patients may benefit from the increased availability of ANKTIVA and its potential to treat various cancers.
• Suppliers may see increased demand for their products and services.
• Creditors may be concerned about the company's ongoing losses and cash burn.

Next Steps

• The company plans to submit a Marketing Authorization Application (MAA) for ANKTIVA in the European Union in Q4 2024.
• ImmunityBio will continue to expand clinical trials globally.
• The company will focus on the regulatory development of ANKTIVA in BCG nave bladder cancer and non-small cell lung cancer (NSCLC) patients who have failed checkpoint inhibitors.

Key Dates

Keywords

ImmunityBio, ANKTIVA, NMIBC, Immunotherapy, Financial Results, J-code, Regulatory Submission, MAA, Product Revenue, Clinical Trials